D.H. Lee

520 total citations · 1 hit paper
16 papers, 386 citations indexed

About

D.H. Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, D.H. Lee has authored 16 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in D.H. Lee's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). D.H. Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). D.H. Lee collaborates with scholars based in South Korea, United States and Switzerland. D.H. Lee's co-authors include Kathryn F. Mileham, Hyun Cheol Chung, Elliot Chartash, Jiaxin Niu, Corinne Maurice‐Dror, Jane Healy, Drew Rasco, Todd M. Bauer, Ulka N. Vaishampayan and Talia Golan and has published in prestigious journals such as Annals of Oncology, American Journal of Neuroradiology and Journal of Thoracic Oncology.

In The Last Decade

D.H. Lee

15 papers receiving 384 citations

Hit Papers

First-in-human phase 1 study of the anti-TIGIT antibody v... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    2021 196 citations Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D.H. Lee South Korea 6 261 147 112 63 43 16 386
Hideki Kuwano Japan 7 137 0.5× 108 0.7× 113 1.0× 57 0.9× 33 0.8× 23 297
Yael Steinberg‐Silman Israel 7 307 1.2× 74 0.5× 56 0.5× 70 1.1× 27 0.6× 8 373
Kageaki Watanabe Japan 10 288 1.1× 65 0.4× 211 1.9× 52 0.8× 43 1.0× 47 406
Yuji Hirami Japan 10 222 0.9× 145 1.0× 162 1.4× 96 1.5× 25 0.6× 21 405
Hisako Okuhira Japan 9 242 0.9× 111 0.8× 67 0.6× 42 0.7× 8 0.2× 14 297
Tomoiki Aiba Japan 7 496 1.9× 107 0.7× 235 2.1× 31 0.5× 15 0.3× 18 544
Catherine Vézina Canada 7 169 0.6× 63 0.4× 45 0.4× 59 0.9× 74 1.7× 12 295
Go Makimoto Japan 10 147 0.6× 26 0.2× 193 1.7× 81 1.3× 15 0.3× 60 298
Ryo Ariyasu Japan 13 273 1.0× 42 0.3× 266 2.4× 81 1.3× 20 0.5× 51 444
F. Mefti France 7 325 1.2× 157 1.1× 107 1.0× 26 0.4× 7 0.2× 15 392

Countries citing papers authored by D.H. Lee

Since Specialization
Citations

This map shows the geographic impact of D.H. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.H. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.H. Lee more than expected).

Fields of papers citing papers by D.H. Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.H. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.H. Lee. The network helps show where D.H. Lee may publish in the future.

Co-authorship network of co-authors of D.H. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of D.H. Lee. A scholar is included among the top collaborators of D.H. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.H. Lee. D.H. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Horinouchi, Hidehito, Benjamin Solomon, Yi‐Long Wu, et al.. (2024). OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 19(10). S39–S39. 1 indexed citations
2.
Peters, Solange, Ana Laura Ortega Granados, Filippo de Marinis, et al.. (2023). LBA64 Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC. Annals of Oncology. 34. S1309–S1309. 2 indexed citations
3.
Lee, D.H., et al.. (2022). 349P EXPLORE-LC: A multi-site real-world evidence research platform for non-small cell lung cancer in Asia-Pacific. Annals of Oncology. 33. S1578–S1578. 1 indexed citations
4.
5.
Niu, Jiaxin, Corinne Maurice‐Dror, D.H. Lee, et al.. (2021). First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Annals of Oncology. 33(2). 169–180. 196 indexed citations breakdown →
6.
Selvaggi, Giovanni, Yi‐Long Wu, Elena Poddubskaya, et al.. (2021). FP14.12 Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.. Journal of Thoracic Oncology. 16(3). S232–S233. 2 indexed citations
7.
Peters, Solange, D.H. Lee, Rodryg Ramlau, et al.. (2021). P14.03 Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy. Journal of Thoracic Oncology. 16(10). S1011–S1012. 3 indexed citations
8.
Ahn, M-J., Jiaxin Niu, Dongwook Kim, et al.. (2020). 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. Annals of Oncology. 31. S887–S887. 26 indexed citations
9.
Niu, Jiaxin, Adnan Nagrial, Mark Voskoboynik, et al.. (2020). 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC. Annals of Oncology. 31. S891–S892. 19 indexed citations
10.
Lee, D.H., D.-W. Kim, D. Ross Camidge, et al.. (2019). Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial. Annals of Oncology. 30. v634–v635. 1 indexed citations
11.
12.
13.
14.
Yoo, Sun Mi, Byung Sup Kim, Jin Hyoung Kim, et al.. (2009). Effect of active smoking on asthma symptoms, pulmonary function, and BHR in adolescents. Pediatric Pulmonology. 44(10). 954–961. 35 indexed citations
15.
Lee, D.H., Cheolwon Suh, Jeong Hyun Lee, et al.. (2007). Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Annals of Oncology. 19(1). 123–127. 42 indexed citations
16.
Pyun, Hae Wook, et al.. (2007). Placement of Covered Stents for Carotid Blowout in Patients with Head and Neck Cancer: Follow-up Results after Rescue Treatments. American Journal of Neuroradiology. 28(8). 1594–1598. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideki Kuwano Breakdown of academic impact, for papers by Yael Steinberg‐Silman Breakdown of academic impact, for papers by Kageaki Watanabe Breakdown of academic impact, for papers by Yuji Hirami Breakdown of academic impact, for papers by Hisako Okuhira Breakdown of academic impact, for papers by Tomoiki Aiba Breakdown of academic impact, for papers by Catherine Vézina Breakdown of academic impact, for papers by Go Makimoto Breakdown of academic impact, for papers by Ryo Ariyasu Breakdown of academic impact, for papers by F. Mefti
Rankless by CCL
2026